ID

18300

Beschrijving

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00493077

Link

https://clinicaltrials.gov/show/NCT00493077

Trefwoorden

  1. 28-10-16 28-10-16 -
Geüploaded op

28 oktober 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Multiple Sclerosis NCT00493077

Eligibility Multiple Sclerosis NCT00493077

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
relapsing-remitting ms according to poser criteria(cdms or lsdms)30 or ms according to mcdonald criteria
Beschrijving

Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis

Datatype

boolean

Alias
UMLS CUI [1]
C0751967
UMLS CUI [2]
C0026769
disability equivalent to an edss of 6.0 or less at screening
Beschrijving

EDSS

Datatype

boolean

Alias
UMLS CUI [1]
C0451246
neutralizing antibody titre > 20 and <500 in two consecutive nab tests. one must be from before screening
Beschrijving

Neutralizing Antibodies Titer | Neutralizing Antibodies Tests Quantity

Datatype

boolean

Alias
UMLS CUI [1,1]
C0475463
UMLS CUI [1,2]
C0475208
UMLS CUI [2,1]
C0475463
UMLS CUI [2,2]
C0392366
UMLS CUI [2,3]
C1265611
previous treatment with either subcutaneous administered interferon-b-1b (betaferon®) or interferon-b-1a (rebif tm) prior to enrolment
Beschrijving

interferon beta-1b Subcutaneous | Betaferon | Interferon beta-1a Subcutaneous | Rebif

Datatype

boolean

Alias
UMLS CUI [1,1]
C0244713
UMLS CUI [1,2]
C1522438
UMLS CUI [2]
C0592527
UMLS CUI [3,1]
C0254119
UMLS CUI [3,2]
C1522438
UMLS CUI [4]
C0752980
a priori has been decided to be treated with avonex
Beschrijving

Avonex

Datatype

boolean

Alias
UMLS CUI [1]
C0594372
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
is nab positive on avonex
Beschrijving

Neutralizing Antibodies Positive Avonex

Datatype

boolean

Alias
UMLS CUI [1,1]
C0475463
UMLS CUI [1,2]
C1514241
UMLS CUI [1,3]
C0594372
history of major depression
Beschrijving

Major Depressive Disorder

Datatype

boolean

Alias
UMLS CUI [1]
C1269683
cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (nyha iii or iv), or significant hypertension (bp > 180/110 mmhg)
Beschrijving

Heart failure | Cardiomyopathies | Cardiac Arrhythmia Significant | Myocardial Ischemia Unstable | Myocardial Ischemia Advanced | New York Heart Association Classification | Hypertensive disease Significant | Blood Pressure

Datatype

boolean

Alias
UMLS CUI [1]
C0018801
UMLS CUI [2]
C0878544
UMLS CUI [3,1]
C0003811
UMLS CUI [3,2]
C0750502
UMLS CUI [4,1]
C0151744
UMLS CUI [4,2]
C0443343
UMLS CUI [5,1]
C0151744
UMLS CUI [5,2]
C0205179
UMLS CUI [6]
C1275491
UMLS CUI [7,1]
C0020538
UMLS CUI [7,2]
C0750502
UMLS CUI [8]
C0005823
renal insufficiency defined as serum creatinine > 1.5 times the upper normal reference limit
Beschrijving

Renal Insufficiency | Creatinine measurement, serum

Datatype

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
any systemic disease that can influence the patient's safety and compliance, or the evaluation of the disability
Beschrijving

Systemic disease Affecting patient safety | Systemic disease Compliance behavior Limited | Systemic disease Affecting Disability Evaluation

Datatype

boolean

Alias
UMLS CUI [1,1]
C0442893
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C1113679
UMLS CUI [2,1]
C0442893
UMLS CUI [2,2]
C1321605
UMLS CUI [2,3]
C0439801
UMLS CUI [3,1]
C0442893
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C0231170
UMLS CUI [3,4]
C1261322
women who are pregnant, breast-feeding or have the possibility for pregnancy during the trial. to avoid pregnancy, women have to be postmenopausal, surgical sterile, sexually inactive or practice reliable contraceptives
Beschrijving

Pregnancy | Breast Feeding | Postmenopausal state | Female Sterilization | Sexual Abstinence | Contraceptive methods

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0232970
UMLS CUI [4]
C0015787
UMLS CUI [5]
C0036899
UMLS CUI [6]
C0700589

Similar models

Eligibility Multiple Sclerosis NCT00493077

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis
Item
relapsing-remitting ms according to poser criteria(cdms or lsdms)30 or ms according to mcdonald criteria
boolean
C0751967 (UMLS CUI [1])
C0026769 (UMLS CUI [2])
EDSS
Item
disability equivalent to an edss of 6.0 or less at screening
boolean
C0451246 (UMLS CUI [1])
Neutralizing Antibodies Titer | Neutralizing Antibodies Tests Quantity
Item
neutralizing antibody titre > 20 and <500 in two consecutive nab tests. one must be from before screening
boolean
C0475463 (UMLS CUI [1,1])
C0475208 (UMLS CUI [1,2])
C0475463 (UMLS CUI [2,1])
C0392366 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
interferon beta-1b Subcutaneous | Betaferon | Interferon beta-1a Subcutaneous | Rebif
Item
previous treatment with either subcutaneous administered interferon-b-1b (betaferon®) or interferon-b-1a (rebif tm) prior to enrolment
boolean
C0244713 (UMLS CUI [1,1])
C1522438 (UMLS CUI [1,2])
C0592527 (UMLS CUI [2])
C0254119 (UMLS CUI [3,1])
C1522438 (UMLS CUI [3,2])
C0752980 (UMLS CUI [4])
Avonex
Item
a priori has been decided to be treated with avonex
boolean
C0594372 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Neutralizing Antibodies Positive Avonex
Item
is nab positive on avonex
boolean
C0475463 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C0594372 (UMLS CUI [1,3])
Major Depressive Disorder
Item
history of major depression
boolean
C1269683 (UMLS CUI [1])
Heart failure | Cardiomyopathies | Cardiac Arrhythmia Significant | Myocardial Ischemia Unstable | Myocardial Ischemia Advanced | New York Heart Association Classification | Hypertensive disease Significant | Blood Pressure
Item
cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (nyha iii or iv), or significant hypertension (bp > 180/110 mmhg)
boolean
C0018801 (UMLS CUI [1])
C0878544 (UMLS CUI [2])
C0003811 (UMLS CUI [3,1])
C0750502 (UMLS CUI [3,2])
C0151744 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C0151744 (UMLS CUI [5,1])
C0205179 (UMLS CUI [5,2])
C1275491 (UMLS CUI [6])
C0020538 (UMLS CUI [7,1])
C0750502 (UMLS CUI [7,2])
C0005823 (UMLS CUI [8])
Renal Insufficiency | Creatinine measurement, serum
Item
renal insufficiency defined as serum creatinine > 1.5 times the upper normal reference limit
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Systemic disease Affecting patient safety | Systemic disease Compliance behavior Limited | Systemic disease Affecting Disability Evaluation
Item
any systemic disease that can influence the patient's safety and compliance, or the evaluation of the disability
boolean
C0442893 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C0442893 (UMLS CUI [2,1])
C1321605 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
C0442893 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0231170 (UMLS CUI [3,3])
C1261322 (UMLS CUI [3,4])
Pregnancy | Breast Feeding | Postmenopausal state | Female Sterilization | Sexual Abstinence | Contraceptive methods
Item
women who are pregnant, breast-feeding or have the possibility for pregnancy during the trial. to avoid pregnancy, women have to be postmenopausal, surgical sterile, sexually inactive or practice reliable contraceptives
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0232970 (UMLS CUI [3])
C0015787 (UMLS CUI [4])
C0036899 (UMLS CUI [5])
C0700589 (UMLS CUI [6])

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial